Engflag

Hepacure

Quick links to important sections

Hepacure

Hepacure_DA

Method of action: Detoxifying, Enzymes, Hepatoprotective, Hypoazotemic

Treatment option: Alcohol Intoxication, Hepatitis, Colic, Coma, Hepatic Encephalopathy, Steatohepatitis, Cirrhosis, Encephalopathy

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hepacure

Property Description
Active ingredient L-Ornithine-L-Aspartate (L-OLA)
Form Oral granules/tablets; Intravenous solution
Pharmacological class Hepatic support agent; Nitrogen metabolism regulator
Common purpose Supporting the detoxification of ammonia
Origin Derived from endogenous amino acids

Chemical Identity and Pharmacological Classification

Hepacure is a pharmaceutical preparation containing the active substance L-Ornithine-L-Aspartate (L-OLA), which is formally classified as a hepatic support agent and a nitrogen metabolism regulator. The medication's general purpose is to augment the body's natural capacity for ammonia detoxification by providing metabolic substrates. L-Ornithine-L-Aspartate is clinically recognized for its role in supporting the clearance of ammonia from the blood. This supportive action is intended to mitigate the metabolic stress placed on the liver when its function is impaired, offering support where nitrogenous waste management needs assistance.

Composition, Origin, and Available Forms

The medication is based on the compound Ornithine aspartate (INN), a stable salt of two amino acids (L-Ornithine and L-Aspartate). Because its components are naturally occurring, L-OLA is considered a bio-derived compound that bolsters the function of the body's internal waste processing pathways. L-Ornithine-L-Aspartate is manufactured as a single-entity product and is available in forms suitable for both oral administration (such as granules for solution or tablets) and for intravenous infusion (parenteral solution). The availability across both routes is intended to offer flexibility in delivering targeted metabolic support based on a patient's specific needs, further distinguishing its therapeutic application.

What side effects are possible with Hepacure?

The safety profile of Hepacure, containing L-Ornithine-L-Aspartate (L-OLA), is officially documented by government regulatory agencies through a system of classified adverse reactions and restrictions. The most frequently observed adverse reactions affect the Gastrointestinal Disorders system-organ class.

Adverse Reaction Classifications

Official prescribing information often classifies common side effects, such as Nausea and Vomiting, as Uncommon (occurring in fewer than 1 in 100 patients). Other reported reactions include stomach pain, diarrhea, flatulence, a sensation of heat, and palpitation. Hypersensitivity reactions, including rash and itching, are generally categorized as Rare.

For the intravenous solution, reactions at the injection site, such as redness or bruising, are sometimes noted, though their frequency is often Not Known due to reporting variability. Gastrointestinal symptoms related to intravenous administration are documented as being transient; these effects are related to the infusion rate and typically resolve upon reduction of the rate.

Safety Restrictions and Population Notes

The medicine is contraindicated in patients with a known hypersensitivity to L-Ornithine-L-Aspartate or any of its components. A major restriction concerns individuals with severely impaired renal function, with regulatory labels defining a serum creatinine level exceeding 3 mg/100 mL as a general guideline for this contraindication.

For Pregnancy and Lactation, official regulatory documents indicate that reliable clinical data are insufficient, and the administration of the medicine in these populations is generally advised to be avoided. The safety profile maintains its non-instructional focus by strictly reporting these classification tiers and limitations as defined by health authorities.

Overdose and Emergency Response

Overdose and when to seek help

The information in this section strictly reflects the officially documented overdose profile and mandated emergency actions as described in government regulatory documents.

Documented Overdose Manifestations

Official regulatory labeling for L-Ornithine-L-Aspartate (L-OLA) states that the recognized clinical signs of overdose are primarily gastrointestinal disturbances. These manifestations are generally considered an exaggeration of known side effects. Specifically, the documented symptoms include nausea, vomiting, and diarrhea.

Required Emergency Actions

Regulatory authorities mandate specific actions for a suspected overdose, emphasizing the need for professional clinical management:

  • Seek immediate medical attention for any suspected overdose or ingestion of excessive amounts.
  • Treatment must be symptomatic and supportive, as the regulatory profile explicitly states that no specific antidote is known for L-OLA.
  • Hospital monitoring and clinical observation may be required based on the severity and persistence of the symptoms presented by the patient.

Regulatory Context

This medication's overdose management is defined by the absence of a specific reversal agent, directing intervention toward continuous supportive care under clinical supervision. This approach is standard for managing presentations characterized by exaggerated known symptoms rather than unique toxicities. Although severe renal impairment is a consideration during standard use, no specific unique overdose severity is detailed for this population in the official overdose sections.

Therapeutic Uses of Hepacure

L-Ornithine-L-Aspartate is used for its role in supporting the management of neurological changes in patients with cirrhosis.

Addressing Neurocognitive Impairments

Hepacure is relevant within the domain of Hepatology, where it is applied to address symptom clusters associated with Hepatic Encephalopathy (HE). It is commonly used across conditions where functional stability is affected, including acute episodes and for chronic management in patients with liver conditions. This medication assists with managing symptoms of increased neurological activity, such as confusion, impaired attention, disorientation, and sleep-wake cycle disturbances. Providing this supportive therapeutic benefit may assist patients in restoring mental clarity and contributes to improved cognitive performance. The use is applicable within clinical settings that involve acute or disruptive symptom patterns.

“The supportive benefit helps improve day-to-day comfort during symptomatic periods.”

In situations where patients experience these episodic or fluctuating manifestations, Hepacure supports patients during difficult episodes by easing distress and assists with maintaining functional stability.

Quick Fact: Relief for Neurocognitive Symptoms

This therapy is relevant for easing the symptoms that interfere with daily functioning, addressing manifestations of HE across episodic or fluctuating manifestations.

Eligibility and Restrictions for Use

Official Eligibility Rules and Restrictions

Regulatory documentation defines strict population eligibility criteria for the use of Hepacure (L-Ornithine-L-Aspartate), based on the patient’s clinical status and age.

Eligibility Status Defined Population and Restriction
Allowed Adults with latent or manifest hepatic encephalopathy.
Contraindicated Patients with known hypersensitivity to the drug or excipients.
Contraindicated Patients with severely impaired renal function (renal insufficiency).
Conditional Use Pregnancy and Lactation; administration should be avoided due to absent human data. Use is only permitted following a strict benefit-risk assessment.
Not Established Pediatric patients (use in children and adolescents is not established due to limited clinical data).

Absolute Prohibitions

The most critical restriction is the absolute contraindication in the presence of severely impaired renal function. Regulatory guidelines specify this as a serum creatinine value over 3 mg/100 ml or 265 mu mol/l. Furthermore, specific oral formulations of the medicine are contraindicated for patients with hereditary fructose intolerance, a restriction based on the presence of excipients in those forms. These eligibility statements define the population that can safely receive the medicine according to governmental labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Regulatory Interaction Status

Official regulatory documents, including those from major governmental health authorities, characterize the interaction profile of L-Ornithine-L-Aspartate (Hepacure) as having no known significant drug–drug, food, or supplement interactions.

This status reflects that the active substance, L-Ornithine-L-Aspartate, is an endogenous amino acid salt, and its metabolic profile generally does not interfere with the clearance or exposure of co-administered medicinal products. The regulatory label does not document specific interactions related to major metabolic pathways, such as CYP450 enzymes or drug transporters, that would necessitate dose adjustments or restrictions.

Combination Restrictions and Constraints

The only specific mandatory combination constraint documented pertains to excipients in the oral formulation. The use of oral Hepacure products containing fructose is formally classified as a contraindication for patients with conditions such as hereditary fructose intolerance.

No mandatory timing rules require the separation of L-Ornithine-L-Aspartate administration from other medicines or food. The interaction status with alcohol is generally noted in regulatory texts as unknown or not formally reported, meaning no specific interaction data is available.

Mechanism of Action

How Hepacure Works: Mechanism of Action

Hepacure acts as an indirect inhibitor that primarily targets the core regulatory complex of the Hippo signaling pathway within hepatocytes (liver cells). The initial molecular action involves the attenuation of Large tumor suppressor kinases 1 and 2 (LATS1/2) kinase activity. This modulation prevents the phosphorylation of the transcriptional co-activators, YAP (Yes-associated protein) and TAZ.

This lack of phosphorylation permits the active YAP and TAZ proteins to translocate from the cytoplasm into the cell nucleus, initiating the key mechanistic cascade. In the nucleus, YAP/TAZ bind to TEAD transcription factors, activating a genetic program that promotes hepatocyte survival and proliferation. The resulting physiological consequence is a pro-proliferative cellular state, characterized by an increase in liver cell mass and structural component rebuilding, which provides the physiological foundation for the drug's overall profile.

Dosage and Administration Information

How to Use Hepacure

Hepacure (L-Ornithine-L-Aspartate) is administered via two primary routes, based on the severity of the patient's condition.

Administration Routes and Standard Dosing

Administration Route Typical Adult Dosing Use Context & Preparation
Oral (Granules/Tablets) 1 to 2 sachets ( 3 g to 6 g L-OLA) taken once or twice daily. For long-term management or less severe conditions. Granules must be dissolved in a large amount of liquid (e.g., water, tea, or juice) and taken after meals.
Intravenous (IV) Infusion Standard: Up to 4 ampoules (up to 20 g) per day. Acute/Severe: Up to 8 ampoules (up to 40 g) within 24 hours. Reserved for acute episodes (e.g., pre-coma or coma). The concentrate must be diluted into a compatible infusion solution before use.

Administration Requirements and Constraints

Intravenous infusion has specific constraints governing its proper administration. The maximum rate of infusion must not exceed 5 g of L-Ornithine-L-Aspartate per hour. For safety and tolerability, the concentrate must be administered only via a vein and not into an artery.

The choice of route is directly tied to the severity of the condition, with the IV route and its higher dose schedule being reserved for the acute setting, while the oral route provides a maintenance option. The medication's use is also constrained by a population-specific restriction: it must not be used in patients with severe renal impairment, generally defined as a serum creatinine level exceeding 3 mg/100 mL.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hepacure

Evidence for Use in Hepatic Encephalopathy

Research for Hepacure (L-Ornithine-L-Aspartate) has studied conditions characterized by fluctuating or episodic manifestations, with a focus on Hepatic Encephalopathy (HE). The available evidence includes Randomized Controlled Trials (RCTs) and large-scale Systematic Reviews and Meta-Analyses. These studies were designed to explore how the compound was studied for adult patients with liver cirrhosis, a population where changes in mental function were observed.

These studies were conducted during periods of increased symptom activity and were designed to explore how this compound was associated with outcomes related to functional change. Researchers monitored changes in the Mental State Grade and Blood Ammonia Concentrations, as well as measures of Neurocognitive Function. Findings describe patterns observed in the studies related to measured changes in neurological status in patients with both acute HE episodes and milder, less noticeable changes (Minimal HE).

Follow-up and Extended-Duration Research

Follow-up durations vary across the research. For acute clinical scenarios, research often has a short-term follow-up duration, sometimes lasting only a few days for intravenous administration. For oral forms, studies observing responses over defined time intervals extend longer, such as a few months. However, long-term effects are not fully established regarding sustained or chronic use. Research currently provides context on symptom patterns over defined, limited time intervals, but there is limited information for long-term outcomes that relate to the persistence of measured changes.

Evidence Gaps and Areas for Future Study

While the overall evidence base is classified as high-level due to the number of available meta-analyses, some key limitations have been noted. Evidence quality varies across studies, and issues of heterogeneity in trial designs are often cited. Furthermore, the existing research provides limited insight into major, long-term clinical endpoints like overall survival. Data for certain groups, such as pediatric patients, remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Hepacure (FAQ)

Q: What is Hepacure used for?

Hepacure is a diuretic (water pill) approved to treat high blood pressure (hypertension) and swelling (edema) caused by conditions such as heart failure, liver problems, or kidney disease. Its action involves helping the body excrete extra salt and water, contributing to a reduction in blood volume and pressure.

Q: How long does it take for Hepacure to start working?

The effects of Hepacure on blood pressure are generally not immediate. While increased urination may be noticed within a few hours, the full benefit in lowering blood pressure may require several weeks of consistent use.

Q: Can I stop taking Hepacure if my blood pressure is back to normal?

Official prescribing information indicates that users should not discontinue the medication without consulting a healthcare professional. High blood pressure is often a chronic condition requiring continuous management. Abruptly discontinuing the drug may cause blood pressure to rise again, potentially increasing the risk of cardiovascular events.

Q: What should I do if I miss a dose of Hepacure?

Product information or a healthcare provider should be consulted for specific instructions on managing a missed dose, as directions vary depending on the drug and dosing schedule. It is generally advised not to take two doses at the same time to compensate for a missed one.

Q: Does Hepacure cause weight loss?

Hepacure can cause some initial weight loss, but this is typically a result of the diuretic effect, which removes extra water and salt from the body. It is not approved or intended for use as a weight-loss drug. Users should consult with a healthcare professional regarding any significant or unexpected changes in weight.

How should Hepacure be stored and disposed of?

How to Store and Dispose of Hepacure

Official regulatory documents define strict conditions for the storage and disposal of Hepacure (L-Ornithine-L-Aspartate) to maintain its quality and ensure environmental safety.

Storage Requirements

Hepacure must be stored in the original container or pack and must not store above 30°C (86°F).

The medicine should be kept in a dry and well-ventilated place and must be protected from both light and moisture.

For child safety, it is a mandatory requirement to store Hepacure out of the sight and reach of children.

Do not use the medicine after the expiry date printed on the packaging.

Disposal Instructions

Unused or expired Hepacure must not be thrown away via household waste or wastewater.

To dispose of the product properly and help protect the environment, individuals must ask a pharmacist for guidance on pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagTaiwan

Equivalent of Hepacure found in:

A-Z Index: